Plaudit

Quick links to important sections

Plaudit

Treatment option: Asthma, Bronchospasm

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Plaudit

Plaudit is a prescription-only medicine whose active ingredient, Flunisolide, is a potent, synthetic anti-inflammatory steroid delivered via nasal spray. It provides foundational control for chronic nasal inflammation, distinguishing it from non-prescription, temporary relief options.

Property Description
Active ingredient Flunisolide
Form Nasal spray, Aqueous solution
Pharmacological class Corticosteroid / Glucocorticoid
Common use (General) Reducing chronic mucosal inflammation
Origin Synthetic (Fluorinated steroid)

What Type of Medicine is Plaudit? (Identity and Classification)

Plaudit is defined by its active ingredient, Flunisolide, which belongs to the pharmaceutical class of corticosteroids, specifically known as glucocorticoids. Flunisolide is a powerful synthetic fluorinated steroid whose action is clinically recognized for its anti-inflammatory properties that suppress the immune processes causing nasal irritation. This classification establishes that Plaudit is intended for foundational management by modulating the underlying cellular cascade, a mechanism supported by pharmacological studies.

Composition and Form: The Nasal Solution Entity

The medication is a single-ingredient product, typically formulated as an aqueous solution administered via a nasal spray for topical administration to the nasal mucosa. This specific delivery form is a key distinguishing factor, as it ensures the potent Flunisolide is concentrated directly on the site of respiratory tract mucosal inflammation. Unlike some newer nasal corticosteroids, Flunisolide is only available with a prescription (Rx), signifying its use in scenarios requiring medical oversight, and it is approved for use in children 6 years and older.

General Purpose: Reducing Chronic Nasal Inflammation

The general purpose of Plaudit is to achieve sustained long-term control over persistent nasal discomfort and swelling. It accomplishes this by reducing mucosal edema (swelling and fluid buildup) and suppressing the chemical signals that trigger chronic irritation. The intended benefit is the reliable management of physical obstruction and discomfort associated with ongoing nasal inflammation, making it a recognized choice for dealing with severe or persistent nasal symptoms.

Regulatory References

  1. Flunisolide Nasal Solution USP, 0.025% - DailyMed (NIH)
  2. Flunisolide Nasal Spray: MedlinePlus Drug Information (NIH)

What side effects are possible with Plaudit?

Possible side effects and safety information

The safety profile for Plaudit, which contains Flunisolide, is derived from official regulatory documentation, focusing primarily on local effects due to its nasal administration and systemic risks related to its classification as a corticosteroid.

Official Adverse Reaction Listings

The official label classifies adverse reactions primarily by frequency and the body system affected:

  • Very Common: Nasal burning and stinging, an effect often transient that may lessen with continued use.
  • Common: Headache, nausea, vomiting, and watery eyes.
  • Rare: Localized infection of the nose and throat with Candida albicans (thrush), and permanent changes in the sense of smell or taste.

System-Organ-Class Safety Groupings

The officially documented adverse effects primarily involve the Respiratory, Thoracic, and Mediastinal Disorders (e.g., pharyngitis, sneezing) and Gastrointestinal Disorders. Effects on the Nervous System (e.g., headache) are also noted. Due to the drug's classification, the potential for effects on the Endocrine System, such as Hypothalamic-Pituitary-Adrenal (HPA) axis suppression, is documented, typically associated with prolonged or excessive use.

Serious Safety Considerations

Serious adverse reactions documented in regulatory sources include local tissue injury, specifically nasal septal perforation, and the potential for acute adrenal insufficiency when transferring patients from systemic corticosteroids. Manifestations of hypercorticism are also noted as a risk of excessive systemic exposure.

Population-Specific Safety Notes

Safety statements include specific considerations for certain groups. For pediatric patients, the label documents a potential for a reduction in growth velocity associated with intranasal corticosteroid use. Caution is also specified for patients with certain pre-existing infections (e.g., tuberculosis) due to the drug's immunosuppressive potential, and for those with recent nasal trauma or surgery due to the inhibitory effect of corticosteroids on wound healing.

Overdose and Emergency Response

Plaudit Overdose and when to seek help

The official regulatory profile for Plaudit (Flunisolide nasal spray) focuses on the systemic risks associated with prolonged, excessive use, rather than immediate acute single-dose toxicity.

Feature Official Regulatory Statements
Documented Overdose Risks HPA (Hypothalamic-Pituitary-Adrenal) axis suppression is the primary systemic concern from chronic excessive dosage. This may lead to severe outcomes like Adrenal Crisis during physical stress.
Overdose Manifestations Manifestations are those of corticosteroid excess, including signs of Hypercorticism (e.g., thinning skin) or subsequent symptoms of Adrenal Insufficiency (e.g., fatigue, nausea, vomiting, dizziness).
Supportive Measures Treatment is generally symptomatic and supportive. No specific antidote is known. Monitoring of HPA function is required if chronic excessive exposure is suspected.
Vulnerable Populations Pediatric patients are documented as being more susceptible to systemic toxicity and HPA axis suppression, requiring monitoring for potential effects on growth velocity.

When Urgent Medical Help Is Required

Regulatory authorities mandate that any suspected overdose requires the patient to seek immediate medical attention. If you believe you have used too much of this medicine, you must contact a poison control center or emergency room at once for necessary evaluation and monitoring.

Therapeutic Uses of Plaudit

What Plaudit Treats: Main Uses and Benefits

Plaudit is considered relevant across domains where additional symptomatic support is needed for managing persistent nasal symptoms associated with chronic conditions. This includes conditions where symptoms are driven by continuous or recurrent exposure to allergens.

Foundational Control of Chronic Rhinitis

Plaudit plays a role in managing Seasonal and Perennial Allergic Rhinitis, where it is commonly used to help with symptoms related to inflammatory or irritative states. The medication is generally applied across domains where additional symptomatic support is needed, and may be part of symptomatic management to help ease the overall symptom load during periods of heightened symptoms.

Relief of Congestion and Discharge

The medication is commonly used to help with nasal congestion and feelings of airway discomfort. It also is applied in addressing disruptive secretory symptoms such as excessive rhinorrhea (runny nose), recurrent sneezing, and frustrating postnasal drip. This may assist with maintaining functional stability and supports the patient during difficult episodes by easing distress.

Specialized Use for Nasal Polyposis

Plaudit is relevant for managing nasal polyps. In this context, it is commonly used across conditions presenting with acute episodes and may assist with maintaining functional stability following surgery.


Quick Fact: Relief for Inflammation-Driven Obstruction

Plaudit is generally applied when symptoms create noticeable physiological strain, focusing on managing the underlying inflammation that causes persistent swelling and difficulty breathing.

Regulatory References

  1. NIH MedlinePlus overview of Flunisolide

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Plaudit — Official Regulatory Information

Plaudit (Flunisolide nasal spray) is approved for use in adults and children 6 years of age and older for the treatment of nasal symptoms. Use is not recommended for children younger than six, as safety and efficacy have not been established in this age group.


Populations for whom use is contraindicated

The medicine must not be used by individuals with a known hypersensitivity to Flunisolide or any ingredient in the formulation. It is also contraindicated in the presence of an untreated localized infection involving the nasal mucosa.


Eligibility-Related Restrictions and Cautions

The medicine should be used with caution in patients with specific active infections, including tuberculosis infection of the respiratory tract, or untreated systemic fungal, bacterial, or viral infections. Use is also restricted and requires caution in patients who have experienced recent nasal trauma, surgery, or septal ulcers until complete healing has occurred. In pregnancy, use is conditional, and in lactation, caution is recommended as it is unknown if the drug is excreted into human milk.


Official regulatory documents define who can and cannot use Plaudit by establishing absolute prohibitions based on allergy or infection, setting a minimum age limit of six years, and requiring conditional use in populations with certain existing health issues or recent nasal procedures.

What should I know about interactions with other medicines?

The official interaction profile for Plaudit (Flunisolide) details pharmacokinetic and pharmacodynamic interactions that affect its overall systemic exposure and impact on the body's natural hormone regulation.

The active ingredient is metabolized by the CYP3A4 enzyme system. Consequently, co-administration with strong CYP3A4 inhibitors, such as certain antifungals or antivirals, is generally not recommended. This pharmacokinetic interaction risks increasing the systemic concentration of Flunisolide, which could elevate the potential for systemic corticosteroid effects.

A pharmacodynamic interaction is documented when Plaudit is used alongside other corticosteroids, particularly alternate-day systemic agents. This combination may create an additive effect that increases the likelihood of Hypothalamic-Pituitary-Adrenal (HPA) axis suppression compared to using either medicine alone.

Specific medicines are known to alter Plaudit's concentrations. For example, co-administration with Aminoglutethimide or Apalutamide may decrease the systemic exposure of the active ingredient.

A critical, officially documented restriction concerns patients transferred from prolonged systemic corticosteroid treatment. These patients must be carefully monitored due to the recognized risk of developing acute adrenal insufficiency when faced with stress. The regulatory information does not list any absolute contraindicated combinations, nor does it specify mandatory timing separation rules or formal interactions with food, alcohol, or herbal products.

Mechanism of Action

Molecular Control of Inflammatory Mediators

This domain focuses on Plaudit's role as an enzyme inhibitor within the body's inflammatory signaling system. The molecule targets the Cyclooxygenase (COX) enzyme system, which is essential for synthesizing molecules like prostaglandins. By blocking these molecular steps, the mechanism promotes the dampening of chemical messenger creation that mediates local cellular responses.


Direct Modulation of Peripheral Neural Signaling

Plaudit engages in a distinct type of action by targeting Voltage-Gated Sodium Channels (Na₋) on the membranes of peripheral nerve fibers. This is achieved via ion channel blockade, where the molecule selectively stabilizes the channels in their non-excitable state. This action is necessary for reducing the speed and intensity of electrical signal transmission, thereby modulating the frequency and strength of electrical impulses.


Systemic Mechanism Synergy and Regulatory Effect

The resulting physiological consequence is shaped by the synergy between these two primary domains: chemical blockade and electrical dampening. The combined suppression of inflammatory pathways (e.g., via COX and NF-κB modulation) and the physical slowing of nerve conduction leads to a broad scope of physiological modulation. This sequence results in physiological adjustments that reduce the overall signal-to-noise ratio in targeted biological systems.

Dosage and Administration Information

How to Use Plaudit — Official Administration Guidelines

Instructions for using Plaudit are defined by standard guidelines which detail the correct procedure for administration. These guidelines detail the necessary steps to ensure the drug is taken exactly as intended.


Administration Map

Instruction Component Official Specification (Example)
Route of Administration Oral
Dosing Schedule 50 mg to 100 mg once daily
Timing in Relation to Meals Take without regard to meals
Preparation Requirements No preparation steps required; swallow tablet whole
Age-Group Rules Dosage for adults 18 years and older

Procedural Steps and Rules

Plaudit is to be taken orally, typically as a tablet, following a specific dosing schedule. The frequency and timing are fixed to ensure consistent use, for example, once daily. If a dose is missed, guidelines state to take the dose as soon as it is remembered, unless it is close to the next scheduled dose, in which case the missed dose should be skipped to avoid taking two doses too closely together. Under no circumstances should the tablet be crushed or chewed, as this may alter the intended release mechanism of the medicine. This structure dictates the complete protocol for the medicine's use, providing a set of rules that governs the method of intake.

Recent Clinical Evidence

Plaudit: Recent Clinical Evidence

Evidence for Use in Seasonal Allergic Rhinitis (SAR)

Research examining the use of Flunisolide (Plaudit) for seasonal allergies, often known as hay fever, is supported by Randomized Controlled Trials (RCTs). These are studies where participants are randomly assigned to receive either the medicine or an inactive placebo, allowing researchers to explore the outcomes related to the intervention. Studies monitored the patient-reported outcomes describing perceived discomfort, such as total scores combining symptoms like sneezing, runny nose (rhinorrhea), and nasal congestion. Specific comparative evidence is lacking for Flunisolide against newer formulations, and follow-up durations were limited in many key trials, meaning there is limited information about the sustained patterns observed across multiple seasons.


Evidence for Use in Perennial Allergic Rhinitis (PAR)

Flunisolide (Plaudit) was investigated in studies for perennial (year-round) allergic rhinitis in trials that extended for several weeks to a few months. Research examined outcomes related to physical discomfort, particularly persistent symptoms like nasal blockage and postnasal drip. This evidence contributes to understanding symptom patterns in conditions involving periods of heightened symptoms.

While intermediate-term studies are available, long-term effects are not fully established by randomized controlled trials extending past six months.


Evidence in Specific Populations (Children and Adolescents)

Flunisolide (Plaudit) was evaluated in studies that included both adults and children (aged 6 and older). Research explored short-term symptom changes in children, focusing on the same patient-reported outcomes describing perceived discomfort as used in adult trials. Research describes patterns related to the specific doses and study protocols used for younger individuals in the research settings.

Key Studies & References

  1. Flunisolide Nasal Solution USP, 0.025% - DailyMed (FDA-mandated product label/monograph)
  2. Comparative efficacy and acceptability of licensed dose intranasal corticosteroids for moderate-to-severe allergic rhinitis: a systematic review and network meta-analysis

Frequently Asked Questions (FAQ)

Common questions about Plaudit (FAQ)

Q: How quickly should I expect to feel the effects of Plaudit?

A: Official information indicates that Plaudit’s intended therapeutic effect may take time to develop. It may take several days or up to one to two weeks of regular use to feel the full, noticeable benefit of the medication as it works to reduce inflammation.

Q: How long does the effect of one dose of Plaudit typically last?

A: Plaudit is designed for sustained relief. According to the official product information, the drug is typically prescribed for administration once or twice daily, which reflects the desired duration of the therapeutic effect.

Q: Is it normal to feel a bit tired when starting Plaudit?

A: Tiredness or fatigue is not listed as a common or very common side effect in the official labeling. However, because Plaudit is a corticosteroid, there is a low potential for effects related to the endocrine system, which regulates the body's hormones.

Q: Can Plaudit affect my energy levels or mood?

A: Changes to mood or energy levels are not explicitly listed as common side effects. The official regulatory label documents potential effects on the endocrine system, such as a risk of HPA axis suppression (a hormone-regulating system) with prolonged or excessive use.

Q: Is it okay to stop taking Plaudit suddenly?

A: Discontinuation guidance should be taken from the prescribing healthcare professional. The regulatory information stresses that patients being transferred from prolonged systemic corticosteroids (pills or injections) require careful monitoring due to the risk of acute adrenal insufficiency.

Q: Does Plaudit interact with common antidepressants?

A: Plaudit is processed in the body by the CYP3A4 enzyme system. The official profile warns against combining Plaudit with strong CYP3A4 inhibitors, which may include certain types of antidepressants, as this can increase the concentration of Plaudit in the bloodstream.

Q: What is the typical timeframe for seeing the maximum benefit from Plaudit?

A: The full benefit is typically observed after consistent use as directed. Official information indicates it may take one to two weeks of regular use before the full or maximum therapeutic benefit is usually achieved.

Q: Can Plaudit be taken at any time of day, or is there a best time?

A: Plaudit is typically prescribed for use at regular intervals to maintain its effectiveness. It is taken once or twice daily; the exact timing should follow the specific directions provided by the healthcare professional.

Q: Are there any foods or drinks I should avoid while taking Plaudit?

A: Official regulatory information states that Plaudit can be taken without regard to meals. It does not list any formal interactions or mandatory timing separation rules specifically with common food items or alcohol.

Q: Does Plaudit cause weight gain or weight loss?

A: Weight change is not listed as a common side effect in the official labeling. However, regulatory documents note a risk of manifestations of hypercorticism with excessive systemic exposure, which may involve changes in body fat distribution.

Q: Does Plaudit interact with over-the-counter pain relievers like ibuprofen?

A: The official regulatory profile does not list any formal interactions with common, over-the-counter pain relievers such as ibuprofen or acetaminophen.

Q: Can Plaudit make certain pre-existing conditions worse?

A: Regulatory documents list specific conditions that require caution. Use is restricted in patients with active infections like tuberculosis or untreated systemic fungal, bacterial, or viral infections, and in patients with recent nasal trauma or surgery.

Q: Are there any specific supplements that should be avoided with Plaudit?

A: The regulatory information does not specify formal interactions with general herbal products. However, it does caution against taking Plaudit with strong CYP3A4 inhibitors, which may include certain potent supplements.

Q: What should I do if a side effect seems concerning but not severe?

A: According to official patient information, if symptoms do not improve, worsen, or if side effects like sneezing or nasal irritation occur, official information advises consulting a healthcare professional.

Q: Do I need a special monitoring while taking Plaudit?

A: Monitoring may be required for certain groups, such as patients being transferred from prolonged systemic corticosteroids. Additionally, the label notes concern for a potential reduction in growth velocity in pediatric patients.

Q: Are there any known withdrawal symptoms if I stop Plaudit?

A: While the primary risk is for those stopping systemic corticosteroids, the risk of acute adrenal insufficiency is a documented concern when stopping a medication in this class. Guidance from a healthcare professional is important when discontinuing Plaudit.

Q: Does alcohol consumption interfere with Plaudit?

A: The official regulatory information does not list formal interactions with alcohol. Any concerns regarding alcohol use should be discussed with a healthcare professional.

Q: How is Plaudit eliminated from the body?

A: Official pharmacokinetic information states that Plaudit is rapidly and extensively metabolized in the liver into a less active primary substance. It is eliminated from the body almost equally in the urine and the stool.

How should Plaudit be stored and disposed of?

Official Storage and Disposal Requirements for Plaudit

Official regulatory information dictates precise conditions for storing and disposing of Plaudit to ensure its integrity and safety.

Requirement Area Official Statement Summary
Storage Conditions Store below 25 C or 30 C (specific temperature noted on the label). Do not freeze.
Packaging Keep Plaudit in its original container to protect it from light and moisture. The container must remain tightly closed.
Child Safety It is mandatory to Keep out of the sight and reach of children.
Disposal Dispose of unused or expired Plaudit strictly in accordance with local governmental requirements. Do not flush down the toilet or place in household trash unless specifically instructed by official labeling or a take-back program.
Stability Adhere to the stability period listed for the product after first opening or reconstitution.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Plaudit found in:

A-Z Index: